Evidence map›Paper›PMID 40004036›Full record

ArticleInternational journal of molecular sciences2025

Acylcarnitine Profiling in Meningiomas with Different NF2 Mutation Statuses.

Joanna Bogusiewicz, Jacek Furtak, Marcin Birski, Krystyna Soszyńska, Anna Majdańska, Agata Ryfa, Marek Harat, Barbara Bojko

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lipidomic profile of meningiomas harboring different NF2 mutation status.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joanna BogusiewiczDepartment of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089 Bydgoszcz, Poland.ORCID 0000-0003-4429-6854
Jacek FurtakMedical Faculty, Bydgoszcz University of Science and Technology, 85-796 Bydgoszcz, Poland.
Marcin BirskiDepartment of Neurosurgery, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland.ORCID 0000-0001-6011-7559
Krystyna SoszyńskaLaboratory of Clinical Genetics and Molecular Pathology, Department of Medical Analytics, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland.
Anna MajdańskaLaboratory of Clinical Genetics and Molecular Pathology, Department of Medical Analytics, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland.
Agata RyfaLaboratory of Clinical Genetics and Molecular Pathology, Department of Medical Analytics, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland.
Marek HaratMedical Faculty, Bydgoszcz University of Science and Technology, 85-796 Bydgoszcz, Poland.
Barbara BojkoDepartment of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089 Bydgoszcz, Poland.ORCID 0000-0003-3971-9816

Funding

National Science Center 2015/18/M/ST4/00059National Science Center 2019/33/N/ST4/00286
6 · The paper itself

Abstract

The mutation in NF2 is the most common alteration associated with meningioma oncogenesis, and it is related to the loss of a suppressing protein called merlin. At the same time, alterations in energy production are visible in cancer cells, where increased demands for energy are observed. Fatty acid oxidation could be one of the ways cancer cells obtain energy. This metabolic pathway uses the acylcarnitine shuttle system, which is responsible for the acylation of fatty acids and their transport through the mitochondria. Therefore, this study aimed to profile acylcarnitines with short, medium, and long acyl chain lengths in meningiomas to assess their changes in tumors with different NF2 mutation statuses. For the analysis, solid-phase microextraction (SPME) coupled with liquid chromatography-high-resolution mass spectrometry (LC-HRMS) was used. The presented sampling method enabled less invasive and easy collection of the analytes from the studied lesions, which can be crucial for future analysis of potential biomarkers in the surgery room. It was observed that higher levels of these analytes characterized meningiomas with NF2 mutations. Moreover, the increased energy consumption and elevated levels of acylcarnitines show that these analytes can be considered markers of increased fatty acid oxidation in NF2 mutated cells.

Indexed as

CarnitineMeningeal NeoplasmsMeningiomaMutationNeurofibromin 2AdultBiomarkers, TumorFemaleHumansMaleMiddle AgedacylcarnitineBiomarkers, TumorCarnitineNeurofibromin 2NF2 protein, humanacylcarnitinemeningiomamerlinNF2solid-phase microextraction

Identifiers

PMID40004036
PMCPMC11855264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.